title: Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine.
authors: I
authors: I
authors: Petekkaya
authors: G
authors: G
authors: Gezgen
authors: E C
authors: EC
authors: Roach
authors: M
authors: M
authors: Solak
authors: I
authors: I
authors: Gullu
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000401:mortality; D001653:Bile Ducts, Intrahepatic; D018395:CA-19-9 Antigen / Q000097:blood; D000069287:Capecitabine; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D017741:Survivors
chemical_list: D000964:Antimetabolites, Antineoplastic; D018395:CA-19-9 Antigen; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil